DTIL - Precision BioSciences Inc Stock Price, Fair Value and News

$5.05+0.26 (+5.43%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DTIL Price Action

Last 7 days

-1.2%

Last 30 days

-31.4%

Last 90 days

0.4%

Trailing 12 Months

-18.7%

DTIL RSI Chart

DTIL Valuation

Market Cap

66.9M

Price/Earnings (Trailing)

-0.8

Price/Sales (Trailing)

0.79

Price/Free Cashflow

-0.91

DTIL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DTIL Fundamentals

DTIL Revenue

Rev. Growth (Yr)

-97.74%

Rev. Growth (Qtr)

-27.78%

DTIL Earnings

Earnings (TTM)

-83.6M

Earnings Growth (Yr)

-32.55%

Earnings Growth (Qtr)

7.43%

DTIL Profitability

Return on Equity

-502.6%

Return on Assets

-89.4%

Free Cashflow Yield

-109.45%

DTIL Investor Care

Shares Dilution (1Y)

72.82%

Diluted EPS (TTM)

-9.09

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	57.5M	87.6M	75.1M	68.7M
2023	30.6M	46.5M	52.3M	48.7M
2022	102.5M	37.5M	20.8M	25.1M
2021	33.6M	101.4M	118.0M	115.5M
2020	23.8M	19.5M	22.0M	24.3M
2019	14.8M	18.3M	20.7M	22.2M
2018	0	0	0	10.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Precision BioSciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

CEO	Mr. Michael Amoroso
WEBSITE	precisionbiosciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	192

Precision BioSciences Inc Frequently Asked Questions

What is the ticker symbol for Precision BioSciences Inc? What does DTIL stand for in stocks?

DTIL is the stock ticker symbol of Precision BioSciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Precision BioSciences Inc (DTIL)?

As of Wed Dec 03 2025, market cap of Precision BioSciences Inc is 66.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DTIL stock?

You can check DTIL's fair value in chart for subscribers.

Is Precision BioSciences Inc a good stock to buy?

The fair value guage provides a quick view whether DTIL is over valued or under valued. Whether Precision BioSciences Inc is cheap or expensive depends on the assumptions which impact Precision BioSciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DTIL.

What is Precision BioSciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, DTIL's PE ratio (Price to Earnings) is -0.8 and Price to Sales (PS) ratio is 0.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DTIL PE ratio will change depending on the future growth rate expectations of investors.